WO1992005281A1 - Procede de detection de staphylococcus aureus resistant au mesitylene-cephem - Google Patents

Procede de detection de staphylococcus aureus resistant au mesitylene-cephem Download PDF

Info

Publication number
WO1992005281A1
WO1992005281A1 PCT/JP1991/001225 JP9101225W WO9205281A1 WO 1992005281 A1 WO1992005281 A1 WO 1992005281A1 JP 9101225 W JP9101225 W JP 9101225W WO 9205281 A1 WO9205281 A1 WO 9205281A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
probe
methicillin
staphylococcus aureus
resistant staphylococcus
Prior art date
Application number
PCT/JP1991/001225
Other languages
English (en)
Japanese (ja)
Inventor
Keiichi Kamisango
Takeshi Yokota
Keiichi Hiramatsu
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of WO1992005281A1 publication Critical patent/WO1992005281A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Definitions

  • the present invention fights against a method for detecting methicillin / cephum-resistant Staphylococcus aureus and a reagent kit therefor.
  • Methicillin a ceph-resistant Staphylococcus aureus (inethici I 1 in-resistant S, aureus; hereinafter abbreviated as “MRSA”), is simply resistant to narrow-semi-synthetic penici 1 I in (PC). Rather than S. aureus, a narrow area that has been effective against mul tidru resistant S. aureus, which was feared as a cause of nosocomial and intractable infections in the 1950s Resistance to semi-synthetic PC and cefum antibiotics (CE CE) is added as a result of chromosomal alterations (Ken Yokota, Fanoremasia, Vol. 26, No. 3, 226). -230 0 990).
  • MRSA is infected in a patient who suffers from local or systemic burns with reduced protective ability, postoperatively, immunodeficiency, etc.
  • the disease shifts to deep infections such as sepsis, meningitis, pulmonary pulp, and brain abscess
  • deep infections such as sepsis, meningitis, pulmonary pulp, and brain abscess
  • the present inventors have conducted intensive research to develop a method that can detect MRSA more accurately and in a shorter time than the conventional method, and as a result, have decided to use the HPA method (hybridization protection assay). Therefore, they have found that it is possible to more specifically detect MRSA in less time than conventional detection methods, and based on this finding, completed the present invention.
  • the present invention provides the following via a linker arm represented by the general formula (I).
  • a linker arm represented by the general formula (I) We will fight against the method of detecting MRSII using a recognition probe labeled with an acridinium ester represented by the general formula (II). That is,
  • R represents an aliphatic hydrocarbon chain having 0 carbon atoms
  • R. 2 »— C — C 1 represents a protecting group for X
  • m represents an integer of 1 to 3 to obtain Ri R 2 Gato
  • R 2 is (R 2) omega - C one X, 1 or 2 or more carbon with O UNA electron withdrawing that protects the An atom, an oxygen atom, a nitrogen atom, or a halogen atom, or a combination thereof.
  • ⁇ represents 1 or 2.
  • X is a sulfur atom
  • ⁇ represents 1
  • X is an amino group
  • ⁇ represents 1 or 2.
  • X 2 represents a halogen atom or an amino group having a substituent
  • X 3 represents a halogen atom, an amino group or 10-
  • R 3 represents an optionally substituted lower alkyl group or lower alkoxy group.
  • R represents a lower alkyl group, a lower alkoxy group, or an aryloxy group, or R represents a hydrogen atom when X 3 is —0—.
  • R s is an optionally substituted lower alkyl group, lower alkenyl group or aryl group
  • R 6 and R 7 are the same or different and each represents a hydrogen atom, an amino group, a hydroxyl group, a thiol group, or a halogen atom.
  • atom a nitro group, Asechiru group, a lower alkyl group, a lower alkenyl group, Ariru group, a substituted Asechiru group, a substituted lower alkyl group, location ⁇ grade alkenyl group, a substituted Ariru group, a lower alkoxy group or Ariruokishi group
  • R 8 is
  • P represents an integer of 0 to 10.
  • the labeled probe labeled with the atherdymester shown in ⁇ is present in the gene DNA that regulates methicillin resistance in the MRSA in the sample or in the MRSA extracted and amplified from the sample.
  • Hybridized with a gene DNA that defines methicillin resistance, followed by a non-hybridized probe and a hybridized but having one or more base mismatches in the intersection A method for detecting MRSA comprising measuring the amount of chemiluminescence after selectively degrading the labeled part of the probe. It is.
  • the present invention also provides a hybridizer comprising a DNA amplification reagent, and a labeled probe labeled with an acridinium ester represented by the general formula (II) via a linker arm represented by the general formula (I).
  • the present invention relates to a reagent kit for MRSA detection, which comprises a selection reagent for a reaction solution after hybridization and a reaction solution after hybridization.
  • a reagent kit for MRSA detection which comprises a selection reagent for a reaction solution after hybridization and a reaction solution after hybridization.
  • a gene DNA that defines methicillin resistance is extracted from the blood or pus of a patient, and an appropriate region of the obtained DNA is specifically amplified. This is achieved by performing an HPA method using a 25- to 35-mer (for example, 30-mer) oligonucleotide labeled with) as a probe.
  • a PCR method polymerase chain reaction; for the PCR method, see “RK. Saik ⁇ ⁇ et. A 1. Science, 239, 487— 491 (19898) ”), and a method using T7 polymerase and reverse transcriptase.
  • the target and probe for detection can be synthesized with a DNA synthesizer (Affaird Biosystems, Model 380B).
  • the probe is labeled with AE (acrylonismester).
  • AE acrylonismester
  • an amino group having an amino group at its center is introduced into the base sequence width.
  • the synthesized oligonucleotide is purified by a conventional method, and mixed with AE having an active ester dissolved in an organic solvent in a reaction solution containing dimethyl sulfoxide and a buffer such as heptase. .
  • the active ester reacts with the amino group of the linker to produce an AE label of the oligonucleotide.
  • the label position of A E from the end to 5 m er is inappropriate, and insertion between two adjacent bases near the center increases the sensitivity of detection.
  • the amplified target is heated to After reprocessing into single strands, the mixture is mixed with a probe and subjected to hybridization by a conventional method. Hybridization is performed in an acidic buffer, and in order to shorten the reaction time, the reaction is performed in an acidic buffer containing lithium salt, at a temperature of 50 to 70 and a time of 3 to several tens of hours. Do it in minutes. After hybridization, a weak alkaline solution containing a surfactant is added, and if the base sequence of the target and the probe are completely identical, the acrylic ester is hydrolyzed. However, if there is a mismatch, hydrolysis occurs and the amount of chemiluminescence decreases. .
  • the linker represented by the general formula (I) used in the present invention is disclosed, for example, in European Patent Publication No. EP 0 311 312.
  • the AE shown is disclosed in WO 89/024 776 if it is very cool.
  • FIG. 1 is a diagram showing the ⁇ H relationship of the probe and the amplification region of the present invention with respect to the DNA of the mecA gene that defines the methicillin resistance of MRSA.
  • FIGS. 2 to 4 show the degree of target V and the chemiluminescence of the conjugate of the two when the synthetic target was reacted with the seed of the present invention and the monoclonal label probe. It is a graph which shows the fighter with quantity.
  • FIG. 5 shows that, using various strains, the three amplification regions of the mecA M gene in FIG.
  • FIG. 4 is a graph showing the intensity of the amount of chemiluminescence of the strain for each probe when the 3 ⁇ 4 ′ probe was reacted.
  • the analysis of the DNA base sequence was performed using SDC-GENETYX (transmission information processing software) (SDC Software Development Co., Ltd.).
  • a primer having the following nucleotide sequence, a probe, and a target were each synthesized with Trityl 0FF using the above DNA synthesizer, and then separated on an 8% polyacrylamide gel. -Purified on an 18-sep pack column (Millipore).
  • Probe PMECA1-2 CCTAATCTCATATGTGTTC CTGTATTGGCC
  • the present inventors have found that such a combination of primer and probe is particularly suitable for detecting MRSII.
  • the regions to be amplified using the above primers and probes are the following three regions.
  • Amplification region (1) PCR1 (311-637) 327fne.r
  • Primer PRHEC1-1 (311 -330), P HEC1 -2 (618-637) Amplification region (2) PCR2 (719-1110) 392iner
  • the mouth is complementary to the DNA sequence of the mecA gene (the value of force ⁇ ).
  • the primers PRHEC1-1, 2-1,3-1 are the same as the DNA sequence of the mec A gene (values in katakana), and MEC1-2,2-2,3-2 is It is a sequence complementary to the corresponding DNA sequence.
  • the target array is as follows.
  • FIG. 1 shows the genes that regulate the methicillin resistance of MRSA.
  • the position of the primer and the probe with respect to the DNA of (mecA) is shown.
  • the mecA gene used was a plasmid (pMR111) provided by Yokota Laboratory, School of Medicine, Juntendo University.
  • PCR (olymerase chain reaction) The PCR was used to amplify the mecA gene. Specifically, the test was performed under the following conditions. First, the following mixture containing the mec A gene was prepared.
  • the sample was heated at 94 C for 3 min.
  • the solution containing the target 5/1 target solution was diluted to prepare with appropriate distilled water 0 -. 5 containing 0 0 0 0 1 degree), the probe solution 5 1 (1 - 4 X 1 0 5 RLU about ), 2X Hybrid Buffer (0.2M lthium succinate L pH5.E], 183 ⁇ 4 111 h l u in 1 aury I sul fate, 2 mM EDTA / EGTA) 20 ⁇ ⁇ Rlf 2 X Transport Hedia (63 ⁇ 4 1Z li thium 1 aury 1 sul fate, 60 in H sodi um hos hate buffer [pH 6.8], 2fnH EDTA / EGTA) 20 ⁇ ⁇ 1 were mixed and heated at 60 ° C for 15 min.
  • a Selection Buf fer 201 (0.2 H sodium tetraborate [pH 7.6], 5% triton X-100) was further subjected to heat treatment at 60 ° C. for 15 min. The reaction solution was cooled to 0, cooled to 1 minute, and returned to room temperature. The amount of chemiluminescence in the remaining reaction solution was measured with Reader I (Gen-Probe Inc).
  • the primers and probes used in the PCR method are either too short or too long.
  • the length of the primer may be 17 m er or more, and the probe is preferably 25 to 35 m er.
  • primers, probes, and targets were synthesized with the lengths of the primer and probe being 20 m er and 30 m er, respectively.
  • the reaction position (target sequence) of the probe was selected from a region having a relatively high GC content (40 or more), as described above. Was introduced at a position near the center of the probe, and labeled with an acrylic ester.
  • Amplification by the PCR method was performed 30 times using 0.1 g of plasmid (pMR.111). The primer used at this time
  • the HP method was used between the target and the acrylidine ester-labeled probe.
  • the RLU amount of each acrylidine ester-labeled probe added to the reaction system is shown in Table 1. The same RLU amount was used
  • the target star was 0-5000 fmo 1 / ⁇ ss a. Y Although the sensitivity and detection efficiency were slightly different, the target of each probe was 5 — 50 fmo 1 or more. (2) to (4) (Fig. 2 to Fig. 4).
  • the MRS A strain used in this example was cultured and adjusted from a clinical isolate provided by the Department of Bacteriology, Juntendo University School of Medicine.
  • the culture was performed using BHI (Brain Heart)
  • a t — MRSAN o.23 and 52 are more resistant to drugs than normal P, SA m strains, Acceptability is as shown in Table 3.
  • HRSA 35 0.4 ⁇ 10 8 0.05 0.8 0.2 0.2
  • the drug-sensitive strains JU 5 and Sinith C used as controls were provided by the Department of Bacteriology, Juntendo University School of Medicine.
  • the product manufactured by Sanko Junyaku Co., Ltd., and the positive control pMR-111 used were those described in the Journal of the Bacteriological Society of Japan, 45 (1), 373, 199.
  • Probe 1-1 has high specificity and good sensitivity.
  • a reagent kit for MRS A detection comprising the following chemicals was prepared.
  • Taq Buf fer 10mH Tris-Cl (pH8.3), 50ffiH C1, 1.5r «H MgCl:, 0.00n (w / v) gelatin], 2.5U Arnpl i T aq (Perkin Elmer Cetus), Includes each primer. )
  • Hybridization reagent including 15 ⁇ 1 2xHybridization Buffer, 5 // 1 2X Transport Media, 1 ⁇ .1 A ⁇ labeled probe

Abstract

Procédé de détection d'un staphylococcus aureus résistant au mésitylène-céphem consistant à hybrider une sonde marquée à l'aide d'un ester d'acridinum près de sa partie centrale par l'intermédiaire d'un bras de liaison, ladite sonde comprenant une séquence de 25 à 35 bases complémentaires de la séquence de base dans une région spécifiée d'un ADN génique définissant la résistance au mésitylène d'un staphylococcus aureus résistant au mésitylène-céphem, soit avec un ADN génique définissant la résistance au mésitylène, et lequel est présent dans un staphylococcus aureus résistant au mésitylène-céphem contenu dans un échantillon, soit avec un ADN génique définissant la résistance au mésitylène, et lequel est présent dans un staphylococcus aureus résistant au mésitylène-céphem extrait d'un échantillon et amplifié par le procédé d'amplification enzymatique de l'ADN. Le procédé consiste également à décomposer sélectivement la partie marquée d'une sonde non hybridée ainsi que celle d'une sonde qui, bien qu'elle soit hybridée, présente une incompatibilité au niveau d'une ou de plusieurs bases dans le croisement, et à mesurer la chimioluminescence. Ce procédé a permis de faire sans erreur des diagnostics précoces de maladies infectieuses provoquées par le staphylococcus aureus résistant au mésitylène-céphem.
PCT/JP1991/001225 1990-09-14 1991-09-13 Procede de detection de staphylococcus aureus resistant au mesitylene-cephem WO1992005281A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24526990 1990-09-14
JP2/245269 1990-09-14

Publications (1)

Publication Number Publication Date
WO1992005281A1 true WO1992005281A1 (fr) 1992-04-02

Family

ID=17131171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1991/001225 WO1992005281A1 (fr) 1990-09-14 1991-09-13 Procede de detection de staphylococcus aureus resistant au mesitylene-cephem

Country Status (2)

Country Link
AU (1) AU8495291A (fr)
WO (1) WO1992005281A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527628A1 (fr) * 1991-08-13 1993-02-17 Eli Lilly And Company Méthode rapide de détection de staphylocoques résistants à la méthycilline
WO1995013395A1 (fr) * 1993-11-08 1995-05-18 Bayer Aktiengesellschaft Analyseurs specifiques de genes et procedes de determination quantitative de staphylocoques resistant a la methicilline
EP0676641A1 (fr) * 1994-04-11 1995-10-11 Kyowa Medex Co., Ltd. Méthode pour essayer une substance
EP0887424A2 (fr) * 1996-02-23 1998-12-30 Kainos Laboratories Inc. Procede de diagnostic
DE19731292A1 (de) * 1997-07-21 1999-01-28 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Nucleinsäuremolekül, Kit und Verwendung
WO2002082086A2 (fr) * 2001-03-15 2002-10-17 Jacques Schrenzel Methode de dectection directe du staphylocoque dore resistant a la methicilline (sarm)
EP1329518A2 (fr) * 1992-07-07 2003-07-23 Fuso Pharmaceutical Industries Ltd. Sonde pour diagnostiquer des maladies infectieuses liées à Staphylococcus aureus
US7074599B2 (en) * 2002-09-27 2006-07-11 Mayo Foundation For Medical Education And Research Detection of mecA-containing Staphylococcus spp.
US7449289B2 (en) 2001-06-04 2008-11-11 Geneohm Sciences Canada, Inc. Methods for detection and identification of methicillin-resistant Staphylococcus aureus
US7838221B2 (en) 2005-10-11 2010-11-23 Geneohm Sciences, Inc. Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA)
US8163478B2 (en) 2004-01-30 2012-04-24 Syngenta Participations Ag Fertility restoration for Ogura cytoplasmic male sterile Brassica and method
US8518646B2 (en) 2006-12-19 2013-08-27 Geneohm Sciences, Inc. Detection of Staphylococcus aureus and identification of methicillin-resistant Staphylococcus aureus
US11834720B2 (en) 2005-10-11 2023-12-05 Geneohm Sciences, Inc. Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL PATHOLOGY, No. June extra edit, 1990, YUKIO MATSUOKA AND ANOTHER, "Application of non-RI marker DNA probe for examinations", p. 82-91. *
FEBS LETTER, Vol. 221, No. 1, August 1987, SONG MD AND FOUR OTHERS, "Evolution of an inducible penicillintarget protein in methicillin-resistant Staphylococcus aureus by gene fusin", p. 167-171. *
JAPAN BACTERIOLOGICAL JOURNAL, Vol. 45, No. 1, 1990, KEN YOKOTA AND TWO OTHERS, "On a methicillin.cephem resistant mechanism in Coagulase (-) Staphylococci (CNS)", p. 373. *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527628A1 (fr) * 1991-08-13 1993-02-17 Eli Lilly And Company Méthode rapide de détection de staphylocoques résistants à la méthycilline
EP1329518A2 (fr) * 1992-07-07 2003-07-23 Fuso Pharmaceutical Industries Ltd. Sonde pour diagnostiquer des maladies infectieuses liées à Staphylococcus aureus
EP1329518A3 (fr) * 1992-07-07 2003-12-10 Fuso Pharmaceutical Industries Ltd. Sonde pour diagnostiquer des maladies infectieuses liées à Staphylococcus aureus
WO1995013395A1 (fr) * 1993-11-08 1995-05-18 Bayer Aktiengesellschaft Analyseurs specifiques de genes et procedes de determination quantitative de staphylocoques resistant a la methicilline
EP0676641A1 (fr) * 1994-04-11 1995-10-11 Kyowa Medex Co., Ltd. Méthode pour essayer une substance
US5665606A (en) * 1994-04-11 1997-09-09 Kyowa Medex Co., Ltd. Method for assaying a substance using a polyacridinium compound
EP0887424A2 (fr) * 1996-02-23 1998-12-30 Kainos Laboratories Inc. Procede de diagnostic
EP0887424A4 (fr) * 1996-02-23 2003-05-02 Kainos Lab Inc Procede de diagnostic
DE19731292A1 (de) * 1997-07-21 1999-01-28 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Nucleinsäuremolekül, Kit und Verwendung
US7955796B2 (en) 2001-03-15 2011-06-07 Jacques Schrenzel Method for the direct detection of methicillin-resistant staphylococcus aureus
WO2002082086A2 (fr) * 2001-03-15 2002-10-17 Jacques Schrenzel Methode de dectection directe du staphylocoque dore resistant a la methicilline (sarm)
WO2002082086A3 (fr) * 2001-03-15 2003-09-25 Jacques Schrenzel Methode de dectection directe du staphylocoque dore resistant a la methicilline (sarm)
US9777335B2 (en) 2001-06-04 2017-10-03 Geneohm Sciences Canada Inc. Method for the detection and identification of methicillin-resistant Staphylococcus aureus
US7449289B2 (en) 2001-06-04 2008-11-11 Geneohm Sciences Canada, Inc. Methods for detection and identification of methicillin-resistant Staphylococcus aureus
US10577664B2 (en) 2001-06-04 2020-03-03 Geneohm Sciences Canada, Inc. Method for the detection and identification of methicillin-resistant Staphylococcus aureus
US10801074B2 (en) 2001-06-04 2020-10-13 Geneohm Sciences Canada, Inc. Method for the detection and identification of methicillin-resistant Staphylococcus aureus
US7074599B2 (en) * 2002-09-27 2006-07-11 Mayo Foundation For Medical Education And Research Detection of mecA-containing Staphylococcus spp.
US8163478B2 (en) 2004-01-30 2012-04-24 Syngenta Participations Ag Fertility restoration for Ogura cytoplasmic male sterile Brassica and method
US8357837B2 (en) 2004-01-30 2013-01-22 Syngenta Participations Ag Fertility restoration for ogura cytoplasmic male sterile Brassica and method
US7838221B2 (en) 2005-10-11 2010-11-23 Geneohm Sciences, Inc. Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA)
US11834720B2 (en) 2005-10-11 2023-12-05 Geneohm Sciences, Inc. Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx
US8518646B2 (en) 2006-12-19 2013-08-27 Geneohm Sciences, Inc. Detection of Staphylococcus aureus and identification of methicillin-resistant Staphylococcus aureus

Also Published As

Publication number Publication date
AU8495291A (en) 1992-04-15

Similar Documents

Publication Publication Date Title
EP0525095B1 (fr) Sondes d'hybridation derivees de la region d'espacement entre les genes d'arn ribosomique 16s et 23s servant a la detection de microorganismes non viraux
WO1992005281A1 (fr) Procede de detection de staphylococcus aureus resistant au mesitylene-cephem
JP5276648B2 (ja) 抗生物質耐性微生物を同定するための方法およびキット
JPH0231699A (ja) 競合オリゴヌクレオチドのプライミングによる変異の検出法
CA2339035C (fr) Identification des micro-organismes responsables d'infections respiratoires
JP2003518924A (ja) 短い配列の変異体を検出するためのアッセイ
US5536638A (en) Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of Neisseria gonorrhoeae
JP2019512208A5 (fr)
US10683558B2 (en) Selective detection of Haemophilus influenzae
US20080199878A1 (en) Detection, identification and differentiation of eubacterial taxa using a hybridization assay
JPWO2003100095A1 (ja) 標的核酸の検出法
US8911947B2 (en) DNA fragment used as attached to 5′ end of primer used in nucleic acid amplification reaction and use of DNA fragment
US20150031576A1 (en) Real time pcr detection of m. tuberculosis resistant/susceptible to rifampicin and/or isoniazid
JP2006508669A (ja) ブドウ球菌属、腸球菌属、および連鎖球菌属から選択される病原性グラム陽性細菌の検出のための方法
CN101627132A (zh) 用于大肠杆菌检测的dna芯片
CA2150986C (fr) Amorces et sondes d'oligonucleotides pour la detection de bacteries
CA2578401A1 (fr) Detection et identification d'especes du genre serratia a l'aide des genes 16s et 23s
CN108642169A (zh) 检测十种甲氧苄胺嘧啶类药物耐药基因方法及所用试剂盒
US9234248B2 (en) Simultaneous quantitative multiple primer detection of Clostridium difficile
JP2004215542A (ja) 結核菌に含まれる薬剤耐性遺伝子を検出する方法、ｐｃｒ用プライマーペアセット、塩基配列決定用プライマーセット、及び薬剤耐性結核の診断用試薬キット
CN109182563A (zh) 检测20种dfrA类甲氧苄胺嘧啶类药物耐药基因的方法及所用试剂盒
WO2013132443A1 (fr) Détection par pcr en temps réel de complexe de mycobacterium tuberculosis
JP2010515452A (ja) スタフィロコッカス・アウレウス検出用ｄｎａチップ
JPH09103300A (ja) 結核菌ＲＮＡポリメラーゼβサブユニット遺伝子増幅用オリゴヌクレオチドおよびその用途
ES2349090T3 (es) Ensayo multiplex de detección de organismos patogénicos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KR LK LU MC MG MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA